PMC:7228307 / 45543-45666
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"808","span":{"begin":59,"end":66},"obj":"Gene"}],"attributes":[{"id":"A808","pred":"tao:has_database_id","subj":"808","obj":"Gene:2214"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T373","span":{"begin":80,"end":102},"obj":"Body_part"}],"attributes":[{"id":"A373","pred":"fma_id","subj":"T373","obj":"http://purl.org/sig/ont/fma/fma55675"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T29","span":{"begin":80,"end":102},"obj":"Body_part"},{"id":"T30","span":{"begin":88,"end":102},"obj":"Body_part"}],"attributes":[{"id":"A29","pred":"uberon_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0001016"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T798","span":{"begin":59,"end":61},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T799","span":{"begin":80,"end":102},"obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"T800","span":{"begin":80,"end":102},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T801","span":{"begin":80,"end":102},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-sample-Pubtator
{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"808","span":{"begin":59,"end":66},"obj":"Gene"}],"attributes":[{"id":"A808","pred":"pubann:denotes","subj":"808","obj":"Gene:2214"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-sample-sentences
{"project":"LitCovid-sample-sentences","denotations":[{"id":"T264","span":{"begin":0,"end":123},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-sample-PD-UBERON
{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T27","span":{"begin":80,"end":102},"obj":"Body_part"}],"attributes":[{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-sample-UniProt
{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T575","span":{"begin":13,"end":17},"obj":"Protein"}],"attributes":[{"id":"A575","pred":"uniprot_id","subj":"T575","obj":"https://www.uniprot.org/uniprot/Q3C2E2"},{"id":"A576","pred":"uniprot_id","subj":"T575","obj":"https://www.uniprot.org/uniprot/Q13963"},{"id":"A577","pred":"uniprot_id","subj":"T575","obj":"https://www.uniprot.org/uniprot/P19437"},{"id":"A578","pred":"uniprot_id","subj":"T575","obj":"https://www.uniprot.org/uniprot/P11836"},{"id":"A579","pred":"uniprot_id","subj":"T575","obj":"https://www.uniprot.org/uniprot/P08984"},{"id":"A580","pred":"uniprot_id","subj":"T575","obj":"https://www.uniprot.org/uniprot/B4DT24"},{"id":"A581","pred":"uniprot_id","subj":"T575","obj":"https://www.uniprot.org/uniprot/A6NMS4"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-sample-PD-FMA
{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T372","span":{"begin":80,"end":102},"obj":"Body_part"}],"attributes":[{"id":"A372","pred":"fma_id","subj":"T372","obj":"http://purl.org/sig/ont/fma/fma55675"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-sample-PD-MAT
{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T21","span":{"begin":80,"end":102},"obj":"http://purl.obolibrary.org/obo/MAT_0000457"},{"id":"T22","span":{"begin":88,"end":102},"obj":"http://purl.obolibrary.org/obo/MAT_0000026"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-sample-PD-HP
{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T30","span":{"begin":104,"end":112},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T264","span":{"begin":0,"end":123},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":104,"end":112},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}